Lobe Sciences Ltd. Stock News

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF), a biopharmaceutical firm developing innovative medicines for rare diseases, told investors it is exploring strategic alternatives to improve shareholder valu

VANCOUVER, British Columbia--(BUSINESS WIRE)--Company Exploring Alternative Value Creation Opportunities; $500,000 Convertible Note Issued; Balance Sheet Strengthened; AGM Set for 22 July 2024.

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) has announced that Wesley Ramjeet will join its Board of Directors in the coming months. Ramjeet, who is the chief executive and Founder of PPMT Strategic Gro

VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to tre

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) has announced the appointment of Dr Frederick Sancilio to its board of directors. The company, which is focused on developing transformative medicines target

VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to tre

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF), a biopharmaceutical company developing transformative medicines for rare diseases, announced that Dr Harry Jacobson will join its board of directors. Dr.

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) has announced a change in voting control of the company and enhancements to its growth strategy. The biopharmaceutical company said Clearway, a subsidiary of

VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences and Clearway Global to Focus on Creating Value for Shareholders, Identify New Board Members, and Strengthen Company Balance Sheet.

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) has listed a series of significant accomplishments in its pursuit of developing transformative medicines to treat rare diseases, marking 2023 as a groundbrea

VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to tre

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) said a Phase 1 has shown the company's proprietary stabilized psilocin conjugate drug candidate L-130 offers significant therapeutic advantages over the inac

VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to tre

Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBEF) told investors that it reached a significant breakthrough after its lead clinical asset, L-130, surpassed the 12-month stability milestone with no signs of de

VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Reports 12 Months Stability for Lead Psilocin Drug Candidate (L-130).